×

Notch3 Biomarker Results and Updated Data From OncoMed's Phase 1b/2 PINNACLE Clinical Trial Accepted for Presentation at the 16th World Conference on Lung Cancer

REDWOOD CITY, Calif., Aug. 27, 2015 (GLOBE NEWSWIRE) -- New biomarker data related to OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Phase 1b/2 PINNACLE clinical trial of tarextumab (Anti-Notch 2/3, OMP-59R5) in small cell lung cancer (SCLC) will be presented by academic collaborator, Anne Chiang M.D., Ph.D., of the Yale School of Medicine, during a mini oral discussion session at the upcoming 16th World Conference on Lung Cancer taking place September 6-9 in Denver, CO. Details for the presentation are provided below.

Wednesday, September 9, 2015

Mini27.08: NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3)

Lead author: Anne Chiang, M.D., Ph.D., Yale School of Medicine

Session: Mini Oral 27: Biology and Other Issues in SCLC

Location: Colorado Convention Center, Room 605+607

ID: 2999

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.

Contact:
Media & Investors Investors
OncoMed Pharmaceuticals Shari Annes
Michelle Corral Annes Associates
Senior Director, Investor Relations and Corporate Communications shari.annes@oncomed.com
michelle.corral@oncomed.com (650) 888-0902
(650) 995-8373

Source:OncoMed Pharmaceuticals, Inc.